Stock overview
Lantern Pharma Inc. (LTRN)
$2.75-4.18%Aft $2.87 (+4.36%)Market cap $35.1M
Stock Scorer
Scoring…
Analyst consensus
$20.00
- Analysts2
- Implied upside+627.3%
- Target range$15.00 to $25.00
Analyst estimates are opinions, not forecasts of what the stock will do.
SEC filings
| Form | Filed | Description |
|---|---|---|
| SCHEDULE 13G/A | July 23, 2026 | View on EDGAR |
| EFFECT | June 18, 2026 | ,, |
| S-1 | June 12, 2026 | S-1 |
| 8-K | June 2, 2026 | 8-K |
| D | May 21, 2026 | 06b |
| SCHEDULE 13D/A | May 15, 2026 | View on EDGAR |
| 8-K | May 15, 2026 | 8-K |
| 10-Q | May 15, 2026 | 10-Q |
Frequently asked questions
What do analysts expect for LTRN?
2 analysts cover Lantern Pharma Inc. (LTRN). The consensus rating is not rated and the average price target is $20.00, in a range of $15.00 to $25.00.
Are insiders buying or selling LTRN?
We have no qualifying Form 4 insider purchases or sales on record for Lantern Pharma Inc. (LTRN). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see LTRN SEC filings?
Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13G/A filed July 23, 2026.
Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.